Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 9760.024 | 0.8939 | 0.7924 | 1.0234 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 9760.024 | 0.5281 | 0.0717 | 1.0234 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 9760.024 | 0.1708 | -0.6444 | 1.0234 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 10127.049 | 1.1065 | 1.3489 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 10127.049 | 0.9146 | 0.7356 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 10127.049 | 1.0594 | 1.1921 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 10127.049 | 0.9172 | 0.7434 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 10127.049 | 1.1143 | 1.3752 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 10127.049 | 1.0002 | 1.0005 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 10127.049 | 0.9442 | 0.8256 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 10127.049 | 0.4689 | -0.3997 | 0.6294 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 10127.049 | 0.1235 | -0.9279 | 0.6294 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9777.049 | 0.9919 | 0.9742 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9777.049 | 1.0848 | 1.2780 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9777.049 | 0.7851 | 0.3585 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9777.049 | 1.1123 | 1.3709 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9777.049 | 0.9847 | 0.9512 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.267 | uM | 9777.049 | 0.8974 | 0.6822 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 1.33 | uM | 9777.049 | 0.8312 | 0.4881 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 6.67 | uM | 9777.049 | 0.7415 | 0.2399 | 0.6254 | |
| SUM102PT | TNBC | Basal B | Gefitinib | EGFR | ErbB | 33.3 | uM | 9777.049 | 0.6026 | -0.1102 | 0.6254 | |
| SUM1315MO2 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7529.016 | 1.0078 | 1.0269 | 0.5847 | |
| SUM1315MO2 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7529.016 | 0.9581 | 0.8587 | 0.5847 | |
| SUM1315MO2 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7529.016 | 0.9697 | 0.8974 | 0.5847 | |
| SUM1315MO2 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7529.016 | 1.0312 | 1.1079 | 0.5847 |